Company intelligence
Teva Pharmaceuticals
About Teva Pharmaceuticals
Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/
Verified activity
Signals from Teva Pharmaceuticals
30 published signals
Partnerships
Teva Pharmaceuticals will receive an equity stake in Andarta Therapeutics and retain a right of first negotiation to re-acquire rights to the compounds at a future date.
Reported by Teva Pharmaceuticals
Partnerships
Teva Pharmaceuticals and Andarta Therapeutics announced that Andarta Therapeutics has obtained rights to advance Teva's fatty acid synthase (FASN) inhibitor program.
Reported by Teva Pharmaceuticals
Strategy & Corporate Development
Teva Pharmaceuticals implemented its Pivot to Growth strategy and led with real discipline.
Reported by Matt Shields
Presence & Recognition
Teva Pharmaceuticals is investment grade with every agency that rates our debt.
Reported by Matt Shields
Products & Services
Teva Pharmaceuticals updated its website with a fresh design and new content.
Reported by Elke Walther
People
Teva Pharmaceuticals is hiring for a role with a huge impact.
Reported by Matt Shields
Presence & Recognition
Teva Pharmaceuticals India colleagues gathered over a traditional Sadhya for Onam celebrations
Reported by Linda VerPlanck
Capital & Finance
Teva Pharmaceuticals achieved Investment Grade recognition from S&P Global Ratings, joining Moody's and Fitch Ratings in recognizing progress to strengthen its financial profile and execute its Pivot to Growth strategy.
Reported by Teva Pharmaceuticals
Presence & Recognition
Teva Pharmaceuticals attended a conference lined up by KonnectHouse team in London to discuss AI in Procurement.
Reported by Maria Antonova
Capital & Finance
Teva Pharmaceuticals was upgraded to BBB- by S&P Global Ratings, joining Moody's and Fitch Ratings in recognizing its full return to investment grade.
Reported by Richard Francis
Research & Knowledge
Teva Pharmaceuticals shared early vitiligo data in July.
Reported by Robert Kempton
Research & Knowledge
Teva Pharmaceuticals announced topline results from a Phase 2a study evaluating an investigational anti-IL-15 antibody in celiac disease.
Reported by Robert Kempton
Research & Knowledge
Teva Pharmaceuticals granted Fast Track designation for Tev-408, a Teva-discovered anti-IL-15 human monoclonal antibody, as a potential therapy for celiac disease in May 2025.
Reported by Teva Pharmaceuticals
Research & Knowledge
Teva Pharmaceuticals announced positive topline results from a phase 2a study in celiac disease for its anti-IL-15 antibody.
Reported by Teva Pharmaceuticals
Research & Knowledge
Teva Pharmaceuticals announced it is advancing the investigational asset Tev-408 into a Phase 2b study in vitiligo.
Reported by Teva Pharmaceuticals
Products & Services
Teva Pharmaceuticals launched the next Teva Rise challenge for AI-enabled predictive formulation design solutions.
Reported by Riad Dirani
Presence & Recognition
Teva Pharmaceuticals featured Katya Englender in a video showcasing her journey from history's greatest to modern labs.
Reported by Riad Dirani
Presence & Recognition
Teva Pharmaceuticals employee Timea Töltszéki will present on the future of data and analytics at Data Expo on the 9th of September.
Reported by Timea Töltszéki
Research & Knowledge
Teva Pharmaceuticals published positive topline Phase 2a results in celiac disease, meeting its primary endpoint and showing no safety signals observed to date.
Reported by Matt Shields
Presence & Recognition
Teva Pharmaceuticals is attending Data Expo in Utrecht on September 9th and 10th at stand 5, representing multiple industries and united by passion for data.
Reported by Timea Töltszéki
Presence & Recognition
Teva Pharmaceuticals Head of Business Development, Evan Lippman, was featured alongside other pharma leaders in an LSX Congress USA article series on how the industry is approaching partnerships.
Reported by Riad Dirani
People
Teva Pharmaceuticals employee Elke Walther was nominated to the EFPIA Patient Access Board Sponsor Committee (BSC) across Europe.
Reported by Elke Walther
Research & Knowledge
Teva Pharmaceuticals announced positive topline results from a Phase 2a study evaluating TEV 408, an investigational anti-IL-15 antibody, in celiac disease.
Reported by Evan Lippman
Partnerships
Teva Pharmaceuticals entered into a funding agreement with Royalty Pharma to accelerate the clinical development of TEV 408.
Reported by Evan Lippman